Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2003
11/06/2003WO2003030908A3 Inhibitors of the egf receptor for the treatment of thyroid cancer
11/06/2003WO2003030615A3 Biocidal mixture of 2-propenal-releasing polymer and isothiazolones
11/06/2003WO2003028624A3 Levothyroxine compositions and methods
11/06/2003WO2003026589A3 Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
11/06/2003WO2003024397A3 Enhancement of learning and memory and treatment of amnesia
11/06/2003WO2003020218A3 Salvianolic acid b
11/06/2003WO2003018745A3 Method of screening for drug hypersensitivity reaction
11/06/2003WO2003018640A3 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
11/06/2003WO2003016270A3 Selective estrogen receptor modulators
11/06/2003WO2003014080A3 Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
11/06/2003WO2003013549A3 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals
11/06/2003WO2003009855A3 Organo-phosphorous compounds for activating gamma/delta t cells
11/06/2003WO2003007791A3 Interspinous process distraction system and method with positionable wing and method
11/06/2003WO2003004064A3 Products for treating ovarian cancers and for preventing relapses
11/06/2003WO2003002125A3 Combination of aminosugars and cysteine or cysteine derivatives
11/06/2003WO2003000294A8 Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
11/06/2003WO2003000177A3 Stable controlled release pharmaceutical compositions containing pravastatin
11/06/2003WO2002102298A3 Process for the preparation of dispersions
11/06/2003WO2002098916A3 Transcriptional regulator of genes involved in the control of cell growth or cell proliferation. use of said regulator as a therapeutic or diagnostic agent
11/06/2003WO2002096445A3 Food compositions for reducing insulin resistance
11/06/2003WO2002094845A3 Method for stabilising of nucleic acids
11/06/2003WO2002094799A3 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
11/06/2003WO2002085328A3 Method for producing an active ingredient concentrate, and an active ingredient concentrate
11/06/2003WO2002083083A3 Pharmaceutically active compounds and methods of use
11/06/2003WO2002080960A3 Treatment of neuropathologies associated with expression of tnf-alpha
11/06/2003WO2002080895A3 Treatment of malaria with farsenyl protein transferase inhibitors
11/06/2003WO2002076979A8 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
11/06/2003WO2002076482B1 USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS
11/06/2003WO2002076375A3 Process for the preparation of benazepril
11/06/2003WO2002073207A3 Isolated ductal fluid sample
11/06/2003WO2002072100A3 Pharmaceutical composition containing pde v inhibitors and surfactants
11/06/2003WO2002070509A8 Antagonists of mcp-1 function and methods of use thereof
11/06/2003WO2002069993A8 Pharmaceutical composition made of cannabis extracts
11/06/2003WO2002069950A3 Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5
11/06/2003WO2002066667A8 Glucosamine and method of making glucosamine from microbial biomass
11/06/2003WO2002066429A8 Method for producing non-hydrated fexofenadine hydrochloride and a novel crystalline form obtained thereby
11/06/2003WO2002066037A3 Antiviral method of use
11/06/2003WO2002060900A8 Antagonists of mcp-1 function and methods of use thereof
11/06/2003WO2002060491A3 Stabilization of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman
11/06/2003WO2002059117A8 Piperazine- and piperidine-derivatives as melanocortin receptor agonists
11/06/2003WO2002059108A8 Melanocortin receptor agonists
11/06/2003WO2002059107A8 Substituted piperidines/piperazines as melanocortin receptor agonists
11/06/2003WO2002057489A3 Method of determining a chemotherapeutic regimen based on ercc1 and ts expression
11/06/2003WO2002055020A9 Topical testosterone formulations and associated methods
11/06/2003WO2002051983A3 Novel compounds and compositions as cathepsin inhibitors
11/06/2003WO2002046475A3 Method of detecting and treating tuberous sclerosis complex associated disorders
11/06/2003WO2002045708A9 Use of zwitterionic polysaccharides for the specific modulation of immune processes
11/06/2003WO2002040039A3 In vivo use of water absorbent polymers
11/06/2003WO2002038208A9 Device and method for the cessation of smoking
11/06/2003WO2002034266A8 Method for inhibiting cataracts
11/06/2003WO2002034204A3 Calcilytic compounds
11/06/2003WO2002032435A3 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade
11/06/2003WO2002030408A3 Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers
11/06/2003WO2002030257A3 Normalization of defective t cell responsiveness through manipulation of thymic regeneration
11/06/2003WO2002026737A8 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
11/06/2003WO2002024891A9 B7-like molecules and uses thereof
11/06/2003WO2002022138A9 Antibacterial agents and methods of identification
11/06/2003WO2002018369A8 Peptidomimetic protease inhibitors
11/06/2003WO2002005749A3 Crf2 ligands in combination therapy
11/06/2003WO2002004952A3 Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors
11/06/2003WO2002002096A8 Oral compositions comprising host-response modulating agent
11/06/2003WO2001094335A8 Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor
11/06/2003US20030208783 Transcriptional activator fusion proteins which comprises both tetracycline controlled transactivator proteins and reverse tetracycline transactivator proteins
11/06/2003US20030208780 Useful in preparing recombinant cells for diagnosis and therapy of human tumors
11/06/2003US20030208281 Method of and composition for preventing tissue damage
11/06/2003US20030208249 Energy-activated targeted cancer therapy
11/06/2003US20030208084 Sulfonamides and derivatives thereof that modulate the activity of endothelin
11/06/2003US20030208082 Nitrogen compounds such as 4,5-diisopropyl-1-methyl-2-styryl -1H-imidazole, used as glutamate receptor antagonists, for prophylaxis of psychological disorders, as anxiolytic agents and analgesics
11/06/2003US20030208080 Synthesis of epothilones, intermediates thereto and analogues thereof
11/06/2003US20030208079 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for proph7ylaxis of cardiovascular disorders
11/06/2003US20030208076 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents
11/06/2003US20030208069 Method for producing 8-methoxy-quinoline carboxylic acids
11/06/2003US20030208067 Inhibitors of protein kinase for the treatment of disease
11/06/2003US20030208065 Reacting 7-amino-3-vinylceph-3-em-4-carboxylic acid with 2-(2-amino-4-thiazolyl-2(aryl or alkyl)oxycarbonylmethyoxy-iminoacetylthio-)benzothiazole to obtain Cefixime; salt formation with tert-octylamine; crystal structure
11/06/2003US20030208058 B7-like polypeptides and polynucleotides
11/06/2003US20030208042 That show high specificity for nicotinic acetylcholine receptors; are useful in a variety of conditions where localized inhibition of neuronal and/or muscle cell function is desirable
11/06/2003US20030207947 Production of lutein in microorganisms
11/06/2003US20030207946 Also comprises electrokinetic stabilizer such as lysine, arginine or histidine, mono-/di-ethanolamine, sodium (bi)carbonate, tromethamine and/or sodium phosphate
11/06/2003US20030207945 Non-halogenated phenyl substituted phenols, antimicrobial compositions containing the same, and methods of using the same
11/06/2003US20030207944 Aminotetralin derivative for the therapy of cardiovascular diseases
11/06/2003US20030207943 Administering dopamine, serotonin, and norepinephrine reuptake inhibitor (sibutramine) for treatment of neuropsychiatric disorders
11/06/2003US20030207942 Hydroxycitric acid salt composition and method of making
11/06/2003US20030207941 Method of treating vascular endothelial growth factor mediated vascular disorders
11/06/2003US20030207940 Hypericin and hypericum extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics
11/06/2003US20030207939 Novel 3-substituted urea derivatives and medicinal use thereof
11/06/2003US20030207937 Such as ethyl-2,2-4,4-tetramethyl-chroman-6-carboxylate; for retinoid-treatable conditions
11/06/2003US20030207936 Comprises fatty ester modified-polyoxyethylene glycol solubilizers
11/06/2003US20030207933 Compositions and methods for increasing the sensitivity of apoptosis-resistant tumor cells to inducers of apoptosis
11/06/2003US20030207931 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1h-1,2,4-triazole for the treatment of autoimmune diseases
11/06/2003US20030207930 Valsartan salts
11/06/2003US20030207925 Methods of treatment with selective EP4 receptor agonists
11/06/2003US20030207924 Compounds that modulate PPAR activity and methods of preparation
11/06/2003US20030207923 Treatment of autoimmune disease, inflammation and allergy; inhibits release of tumour necrosis factor
11/06/2003US20030207922 Diketoacids useful as inhibitors of viral polymerases, in particular hepatitis C virus, RNA dependent RNA polymerase, hepatitis B virus polymerase and reverse transcriptase of human immunodeficiency virus
11/06/2003US20030207920 N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants
11/06/2003US20030207919 For treating, preventing, reducing inflammation, pain, fever,gastrointestinal disorders; decreasing gastrointestinal, renal and other toxicities resulting from use of nonsteroidal antiinflammatory drugs; multiplicity of compounds
11/06/2003US20030207918 Administering to patient a bolus injection of an active drug, in particular tirofiban, in an amount of 25 mu g/kg, and administering to the patient, after the bolus injection, an intravenous infusion for a period of 12-72 hours of the drug
11/06/2003US20030207917 1,4-di-substituted piperidines, some of which have M2 selectivity even higher than that of 3-alpha-chloroimperialine for treating cognitive disorders such as Alzheimer's disease
11/06/2003US20030207916 Thiazole or oxazole derivatives such as (4-(4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl)-5-oxo -5,6,7,8-tetrahydro-naphthalen-1-yloxy)-acetic acid
11/06/2003US20030207915 Compounds that modulate PPAR activity and methods of preparation
1 ... 5284 5285 5286 5287 5288 5289 5290 5291 5292 5293 5294 5295 5296 5297 5298 5299 5300 5301 5302 5303 5304 ... 7860